 This is the new concept of conservative iron chelation. We recently demonstrated for the first time the feasibility, efficacy and acceptability of the conservative iron chelation approach in pilot translational studies in Parkinsons disease with a prototype drug: deferiprone 1,2-dimethyl-3-hydroxypyridin-4-one in the FAIR-PARK-I project led by the applicant and funded by French Ministry of Health. The only available blood-brain-barrier-permeable iron chelator deferiprone is approved for treating systemic iron overload in transfused patients with thalassemia. Deferiprone has been on the European Union market since 1999, with a favourable riskbenefit balance at dose of 75 to 100 mgkgday. The investigators shall adopt a repositioning strategy by using deferiprone at a lower dose of 30 mgkgday in this new indication for local iron overload in Parkinsons disease. Deferiprone will be the first-in-class drug for this novel therapeutic strategy. On the basis of the preclinical and clinical data from FAIR-PARK-I, the present FAIR-PARK-II project should constitute a model for future cytoprotection strategies in neurodegenerative diseases; if deferiprone treatment is associated with significant slower disease progression, it would be the first non-dopaminergic drug to have a proven disease-modifying effect in Parkinsons disease. 